Annual peak revenue
Search documents
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC)
Seeking Alpha· 2026-03-26 00:16
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]
